Business Context and Reporting Period
This Form 10-Q covers Becton, Dickinson and Company (BD) for the quarterly period ended June 30, 2000, and the nine months ended on that date. BD operates through three principal segments: BD Medical Systems, BD Biosciences, and BD Preanalytical Solutions. The company manufactures medical devices, diagnostic products, and preanalytical solutions.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2000 | Nine Months Ended June 30, 2000 |
|---|---|---|
| Revenues | $914.1 million | $2,698.4 million |
| Net Income | $114.4 million | $308.9 million |
| Diluted EPS | $0.43 | $1.17 |
| Operating Income | $151.3 million | $422.9 million |
| Operating Margin | 16.6% | 15.7% |
| Gross Profit Margin | 50.4% | 48.9% |
| Operating Cash Flow (9mo) | $439.1 million | |
| Total Debt | $1.49 billion ($701M short-term + $788M long-term) | |
| Cash and Equivalents | $76.9 million |
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 5% for the quarter and 7% for the nine months compared to the prior year. Growth was driven by safety-engineered products and recent acquisitions, partially offset by a strengthened dollar which reduced revenues by an estimated $24 million (quarter) and $53 million (nine months).
- Profitability Surge: Net income for the quarter rose significantly from $33.1 million to $114.4 million. This improvement is largely attributable to the absence of $75.6 million in special charges recorded in the prior year's quarter and $64.9 million in net gains on sales of investments in the current period.
- Segment Performance: BD Biosciences revenues grew 10% (quarter) and 14% (nine months). BD Medical Systems grew 3% (quarter) and 4% (nine months). BD Preanalytical revenues remained flat for the quarter but grew 6% for the nine months.
- Debt Reduction: Total debt decreased to $1.49 billion, representing 43.1% of total capital, down from 44.4% a year ago.
Guidance, Outlook, and Risks
- Capital Expenditures: Management expects capital spending for fiscal 2000 to be approximately $400 million, reflecting investment in manufacturing capacity for safety-engineered products.
- Product Recall: In Q2 2000, BD incurred approximately $13 million in recall costs for the BD Insyte AutoGuard shielded IV catheter due to skin irritation reports. Shipments resumed in Q3 after manufacturing adjustments.
- Investment Gains: The company recorded $65 million in net gains on sales of investments for the nine-month period, including a $33 million gain in Q2 and a $29 million gain in Q3 from stock exchanges. These are non-recurring items.
- Legal Proceedings: BD is a defendant in approximately 375 product liability lawsuits regarding natural rubber latex and 11 class action suits regarding needle-stick injuries. Management does not expect these to have a material impact on financial results.
- Foreign Currency: The strengthened dollar negatively impacted revenue and earnings. Management estimates foreign currency translation reduced Q3 EPS by $0.03.
Investor Verification Checklist
- Non-Recurring Gains: Verify the sustainability of earnings by excluding the $65 million in investment gains and the $13 million recall cost.
- Margin Compression: Review the decline in gross profit margin (48.9% for nine months) attributed to the product mix and scaling costs of new safety-engineered devices.
- Working Capital: Note the $59 million decrease in trade receivables due to collection efforts and the $64 million increase in inventory to support Q4 demand.
- Restructuring Accruals: Monitor remaining accruals for the 1998 restructuring plan, specifically regarding the closure of a U.S. surgical blade plant scheduled for fiscal 2002.
- Legal Exposure: Track the status of the latex and needle-stick litigation, although currently deemed immaterial.